AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
Log in

NASDAQ:RZLTRezolute Stock Price, Forecast & News

$0.10
0.00 (0.00 %)
(As of 07/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.08
Now: $0.10
$0.11
50-Day Range
$0.07
MA: $0.10
$0.14
52-Week Range
$0.06
Now: $0.10
$0.50
Volume610,772 shs
Average Volume47,166 shs
Market Capitalization$29.66 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Rezolute, Inc., a clinical stage biopharmaceutical company, specializes in the development of drug therapies for the treatment of patients with metabolic and orphan diseases in the United States. Its products include RZ358, a human monoclonal antibody that is in Phase II clinical trial for the treatment of congenital hyperinsulinism, a devastating ultra-orphan pediatric disease; RZ402, a plasma kallikrein inhibitor, which is in late stage preclinical program for the treatment of diabetic macular edema; and RZ602, a product candidate that is in preclinical trial for the treatment of hereditary angioedema. It also develops AB101, a human recombinant insulin, which is in Phase I clinical trial for the treatment of patients with type 1 and type 2 diabetes mellitus. Rezolute, Inc. has a development and license agreement with ActiveSite Pharmaceuticals, Inc. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.22 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RZLT
CUSIPN/A
CIKN/A
Phone650-206-4507

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees20
Market Cap$29.66 million
Next Earnings DateN/A
OptionableNot Optionable

Receive RZLT News and Ratings via Email

Sign-up to receive the latest news and ratings for RZLT and its competitors with MarketBeat's FREE daily newsletter.

Rezolute (NASDAQ:RZLT) Frequently Asked Questions

How has Rezolute's stock been impacted by COVID-19 (Coronavirus)?

Rezolute's stock was trading at $0.0820 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, RZLT shares have increased by 22.0% and is now trading at $0.10. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Rezolute?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rezolute in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Rezolute.

What price target have analysts set for RZLT?

2 brokers have issued twelve-month price objectives for Rezolute's shares. Their forecasts range from $0.38 to $0.55. On average, they expect Rezolute's share price to reach $0.47 in the next year. This suggests a possible upside of 365.0% from the stock's current price. View analysts' price targets for Rezolute.

Has Rezolute been receiving favorable news coverage?

News coverage about RZLT stock has been trending negative on Monday, according to InfoTrie. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Rezolute earned a daily sentiment score of -2.1 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news about Rezolute.

Who are some of Rezolute's key competitors?

What other stocks do shareholders of Rezolute own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rezolute investors own include Sandstorm Gold (SAND), Xilinx (XLNX), AC Immune (ACIU), Agnico Eagle Mines (AEM), Akoustis Technologies (AKTS), Amplify Energy (AMPY), Amplify Energy (AMPY), ITUS (ANIX), Aptiv (APTV) and Arotech (ARTX).

Who are Rezolute's key executives?

Rezolute's management team includes the following people:
  • Mr. Nevan Charles Elam, CEO & Director (Age 52)
  • Dr. Hoyoung Huh, Founder, Chairman of Scientific Advisory Board & Bus. Dev. & Vice Chairman (Age 50)
  • Dr. Keith A. Vendola, Chief Financial Officer (Age 47)
  • Dr. Sankaram Mantripragada, Chief Scientific Officer (Age 59)
  • Mr. Michael R. Deperro, VP of Operations

What is Rezolute's stock symbol?

Rezolute trades on the NASDAQ under the ticker symbol "RZLT."

How do I buy shares of Rezolute?

Shares of RZLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Rezolute's stock price today?

One share of RZLT stock can currently be purchased for approximately $0.10.

How big of a company is Rezolute?

Rezolute has a market capitalization of $29.66 million. Rezolute employs 20 workers across the globe.

What is Rezolute's official website?

The official website for Rezolute is www.rezolutebio.com.

How can I contact Rezolute?

The company can be reached via phone at 650-206-4507.

This page was last updated on 7/6/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.